The company has reported a total income of Rs.323.17 crores during the period ended June 30, 2021, as compared to Rs.363.19 crores during the period ended March 31, 2021. The company reported a total income of Rs 296.80 crore for the period ended June 30, 2020.

The company has posted net profit / (loss) of Rs.0.873 crores for the period ended June 30, 2021, as against net profit / (loss) of Rs.20.63 crores for the period ended March 31, 2021. The company posted a net profit/(loss) of Rs 15.80 crores for the period ended June 30, 2020.

The company has reported EPS of Rs.0.04 for the period ended June 30, 2021, as compared to Rs.0.84 for the period ended March 31, 2021. The EPS for the period ended June 30, 2020, stood at Rs 0.93.

Commenting on the company's performance, Manish Gupta, Managing Director stated "The quarter gone by has indeed been the most challenging one, both from demand and execution perspective. We are pleased to report an over 15% growth in our formulations business even as our API business reported a de-growth after many quarters of consistent growth. We reported revenues of Rs 320 crores for the quarter, reflecting a growth of 8.9% YoY on a constant currency basis while the EBITDA stood at Rs 35.8 crores excluding ESOP costs.’’

He further added, ``On the business side, we are pleased with continuing strong growth in the key markets of India & LATAM, and we expect improved performance in Europe and Turkey going forward. We shall continue to invest both in expanding our footprints as well as strengthening our presence in existing markets. We expect a strong recovery in our API business in the second half. Our strategy for API business continues to play out well as we continue to improve the quality of business with an ever-increasing contribution of regulated markets business, which now stands at 72% vs. 66% last year.’’